Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity.
Breast cancer
Dose Hypofractionation
Predectifs factors
Regional lymph node hypofractionated radiation
Side effects
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
06
07
2021
accepted:
07
07
2022
pubmed:
10
8
2022
medline:
18
1
2023
entrez:
9
8
2022
Statut:
ppublish
Résumé
The purpose of this study was to evaluate acute skin toxicity in early breast cancer patients treated with hypofractionated radiotherapy (HFRT) after breast-conserving surgery and to identify factors predictive for grade ≥ 2 acute skin toxicity. A monocentric retrospective study was carried out using cases treated between December 2017 and November 2020. We analyzed data from 202 patients with early breast cancer treated with 3D hypofractionated RT (40.05 Gy in 15 fractions) to the whole breast with or without regional lymph nodes, followed by 13.35 Gy in 5 fractions to the tumor bed. Acute skin toxicity was monitored during RT according to CTCAE (common toxicity criteria for adverse events) scale. Univariate and multivariate analyses were performed to assess predictive factors of acute skin toxicity. Overall, there was no erythema in 9%, grade 1 erythema in 64.5%, grade 2 in 24%, and grade 3 in 2.5%. No grade 4 erythema was seen. Median delay between RT initiating and maximum skin reaction was 22 days (range 4-44 days). No patient interrupted treatment. In univariate analysis, the rate of acute skin toxicity grade 2---3 (G2-3) was significantly higher for patients with larger tumor size (p = 0.02), body mass index > 27 (p = 0.04), and time between chemotherapy (CT) and RT less than 20 days (p = 0.01). Dosimetric risk factors for acute skin toxicity G2‑3 were breast volume > 800 cc (p = 0.000), boost volume > 18 cc (p = 0.002), V105% > 40 cc (p = 0.03), and Dmax > 56 Gy (p = 0.007). CT, trastuzumab, regional lymph node radiation, and age were not correlated with increased skin toxicity. In multivariate analysis, acute skin toxicity correlated with T stage (p = 0.032), breast volume > 800 cc (p = 0.012), boost volume > 18 cc (p = 0.04), and Dmax > 56 Gy (p = 0.035). Our results confirm that whole breast with or without lymph nodes hypofractionated RT is safe and well tolerated. The factors strongly associated with a decreased risk of G2‑3 skin toxicity are T1, breast volume < 800 c, boost volume < 18 cc, and Dmax < 56 Gy. Long-term follow-up is needed to evaluate late toxicity.
Identifiants
pubmed: 35943552
doi: 10.1007/s00066-022-01985-4
pii: 10.1007/s00066-022-01985-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48-54Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135
doi: 10.1016/S0140-6736(14)60488-8
START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107
doi: 10.1016/S0140-6736(08)60348-7
Whelan TJ, Kim D‑H, Sussman J (2008) Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol 18(4):257–264
doi: 10.1016/j.semradonc.2008.04.008
Shaitelman SF, Schlembach PJ, Arzu I, et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: A randomized clinical trial. JAMA Oncol 1(7):931–941. https://doi.org/10.1001/jamaoncol.2015.2666
doi: 10.1001/jamaoncol.2015.2666
Murray Brunt A, Haviland JS, Wheatley DA, et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395(10237):1613–1626. https://doi.org/10.1016/S0140-6736(20)30932-6
doi: 10.1016/S0140-6736
CTEP Common terminology criteria for adverse events (CTCAE) | protocol development. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm . Accessed 12.2021
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A et al (2015) ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 114(1):3–10
doi: 10.1016/j.radonc.2014.11.030
Sanz J, Rodríguez N, Foro P, et al (2017) Hypofractionated boost after whole breast irradiation in breast carcinoma: chronic toxicity results and cosmesis. Clin Transl Oncol 19(4):464–469. https://doi.org/10.1007/s12094-016-1548-3
doi: 10.1007/s12094-016-1548-3
Tortorelli G, Di Murro L, Barbarino R, Cicchetti S, di Cristino D, Falco MD et al (2013) Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities. Bmc Cancer 13(1):230. https://doi.org/10.1186/1471-2407-13-230
doi: 10.1186/1471-2407-13-230
Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A et al (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3‑week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol 120(1):114–118
doi: 10.1016/j.radonc.2016.02.027
Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP et al (2016) Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003860.pub4
doi: 10.1002/14651858.CD003860.pub4
Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y et al (2019) A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Jpn J Clin Oncol 49(1):57–62. https://doi.org/10.1093/jjco/hyy160
doi: 10.1093/jjco/hyy160
Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J et al (2005) Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75(1):9–17
doi: 10.1016/j.radonc.2005.01.005
Holloway CL, Panet-Raymond V, Olivotto I (2010) Hypofractionation should be the new ‘standard’ for radiation therapy after breast conserving surgery. Breast 19(3):163–167
doi: 10.1016/j.breast.2010.03.002
Dorn PL, Corbin KS, Al-Hallaq H, Hasan Y, Chmura SJ (2012) Feasibility and acute toxicity of Hypofractionated radiation in large-breasted patients. Int J Radiat Oncol Biol Phys 83(1):79–83
doi: 10.1016/j.ijrobp.2011.05.074
Ciammella P, Podgornii A, Galeandro M, Micera R, Ramundo D, Palmieri T et al (2014) Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors. Radiat Oncol 9(1):97. https://doi.org/10.1186/1748-717X-9-97
doi: 10.1186/1748-717X-9-97
Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C et al (2007) Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 68(5):1375–1380
doi: 10.1016/j.ijrobp.2007.02.044
Hijal T, Al Hamad AA, Niazi T, Sultanem K, Bahoric B, Vuong T et al (2010) Hypofractionated radiotherapy and adjuvant chemotherapy do not increase radiation-induced dermatitis in breast cancer patients. Curr Oncol 17(5):22–27
doi: 10.3747/co.v17i5.604
Kouloulias V, Zygogianni A, Kypraiou E, Georgakopoulos J, Thrapsanioti Z, Beli I et al (2014) Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancer. WJCC 2(11):705–710
doi: 10.12998/wjcc.v2.i11.705
Zygogianni A, Kouloulias V, Antypas C, Armpilia C, Kyrgias G, Kouvaris J (2014) The impact of intermediate time between chemotherapy and hypofractionated radiotherapy to the radiation induced skin toxicity for breast adjuvant treatment. Breast J 20(1):74–78. https://doi.org/10.1111/tbj.12206
doi: 10.1111/tbj.12206
De Langhe S, Mulliez T, Veldeman L, Remouchamps V, van Greveling A, Gilsoul M et al (2014) Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. Bmc Cancer 14(1):711. https://doi.org/10.1186/1471-2407-14-711
doi: 10.1186/1471-2407-14-711
Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K et al (2010) Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 11(3):258–265
doi: 10.1016/S1470-2045(10)70013-9
Keenan LG, Lavan N, Dunne M, McArdle O (2019) Modifiable risk factors for acute skin toxicity in adjuvant breast radiotherapy: dosimetric analysis and review of the literature. Med Dosim 44(1):51–55
doi: 10.1016/j.meddos.2018.01.004
Taher AN, El-Baradie MM, Essa H, Zaki O, Ezzat S (2004) Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reactions and cosmetic results. J Egypt Natl Canc Inst 16(3):178–187
De Santis MC, Bonfantini F, Di Salvo F, Dispinzieri M, Mantero E, Soncini F et al (2016) Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. Breast 29:90–95
doi: 10.1016/j.breast.2016.07.013